LAVA Therapeutics N.V.
LVTX
$1.28
$0.043.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.98M | 7.35M | 7.40M | 12.54M | 6.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.98M | 7.35M | 7.40M | 12.54M | 6.77M |
| Cost of Revenue | 24.55M | 32.71M | 32.72M | 35.11M | 36.04M |
| Gross Profit | -12.57M | -25.37M | -25.33M | -22.57M | -29.27M |
| SG&A Expenses | 13.23M | 12.42M | 12.50M | 13.17M | 14.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.78M | 35.53M | 35.02M | 44.34M | 50.16M |
| Operating Income | -25.79M | -28.18M | -27.62M | -31.81M | -43.39M |
| Income Before Tax | -24.49M | -27.25M | -23.84M | -28.23M | -41.61M |
| Income Tax Expenses | 630.00K | 289.00K | 243.00K | 255.00K | 257.00K |
| Earnings from Continuing Operations | -25.12 | -27.54 | -24.08 | -28.48 | -41.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.12M | -27.54M | -24.08M | -28.48M | -41.87M |
| EBIT | -25.79M | -28.18M | -27.62M | -31.81M | -43.39M |
| EBITDA | -25.33M | -27.62M | -27.03M | -31.18M | -42.78M |
| EPS Basic | -0.94 | -1.03 | -0.90 | -1.08 | -1.59 |
| Normalized Basic EPS | -0.48 | -0.64 | -0.56 | -0.67 | -0.99 |
| EPS Diluted | -0.94 | -1.03 | -0.90 | -1.08 | -1.59 |
| Normalized Diluted EPS | -0.48 | -0.64 | -0.56 | -0.67 | -0.99 |
| Average Basic Shares Outstanding | 107.33M | 107.23M | 106.68M | 106.14M | 105.64M |
| Average Diluted Shares Outstanding | 107.33M | 107.23M | 106.68M | 106.14M | 105.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |